Business, energy, technology, markets and global industry news from Business News Today

AP-101

PharmaDeviceNews AP-101
Representative image: Laboratory research into AP-101 highlights AL-S Pharma’s effort to target misfolded SOD1 and advance a potential new treatment approach for amyotrophic lateral sclerosis.
Pharma & Biotech

AL-S Pharma’s AP-101 Phase 2 data strengthen the misfolded SOD1 strategy in ALS

Read how AL-S Pharma’s AP-101 Phase 2 data strengthen the misfolded SOD1 case in ALS and what its Phase 3 trial must prove.

Read More